Company Profile

Acasti Pharma is a biopharmaceutical innovator that has historically focused on advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. Acasti conducted two Phase 3 clinical trials: the TRILOGY trials. In TRILOGY 1, CaPre® achieved a 30.5% reduction in triglyceride levels at 12 weeks and 36.7% reduction in triglyceride levels at 26 weeks, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks. Despite positive results in the CaPre arm, the TRILOGY 1 study did not reach statistical significance. In TRILOGY 2, CaPre achieved 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint.

Latest Presentation

Industry Classifications



Pharmaceutical Preparation Manufacturing (325412)

Pharmaceutical and Medicine Industry (3741)

Contact Information

Investor Relations
Crescendo Communications, LLC
Chrysler Building
405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020

Company Contact
Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5